Milestone Pharmaceuticals Inc. Current Liabilities
Milestone Pharmaceuticals Inc. (MIST) had Current Liabilities of $22.18 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Liabilities, Current $22.18M.
- 2026-03-31: Liabilities, Current $20.94M.
- 2025-12-31: Liabilities, Current $13.98M.
- 2025-09-30: Liabilities, Current $10.52M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $22.18M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $20.94M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $13.98M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $10.52M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $9.28M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $12.96M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $8.13M 10-K · filed 2026-03-20 |
| 2024-09-30 | $5.26M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $4.57M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $4.13M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $7.23M 10-K · filed 2025-03-13 |
| 2023-09-30 | $8.11M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $6.81M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $7.96M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $6.14M 10-K · filed 2024-03-21 |
| 2022-09-30 | $6.52M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $4.26M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $4.61M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $6.78M 10-K · filed 2023-03-29 |
| 2021-09-30 | $5.85M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $5.33M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $5.82M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $6.16M 10-K · filed 2022-03-24 |
| 2020-09-30 | $5.88M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $4.99M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $5.37M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $8.33M 10-K · filed 2021-03-29 |
| 2019-09-30 | $8.84M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $6.46M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $4.15M 10-Q · filed 2019-06-19 |
| 2018-12-31 | $4.53M 10-K/A · filed 2020-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |